Theralase Technologies Earnings Estimate
Theralase Technologies Earnings per Share Projection vs Actual
About Theralase Technologies Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Theralase Technologies earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Theralase Technologies estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Theralase Technologies fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada. Theralase Technologi operates under Medical Devices classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Theralase OTC Stock
Theralase Technologies financial ratios help investors to determine whether Theralase OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Theralase with respect to the benefits of owning Theralase Technologies security.